Dyne Therapeutics (DYN) Competitors $14.13 -0.64 (-4.33%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DYN vs. LEGN, ELAN, CYTK, NUVL, GRFS, TGTX, VKTX, AXSM, KRYS, and OGNShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Axsome Therapeutics (AXSM), Krystal Biotech (KRYS), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. Legend Biotech Elanco Animal Health Cytokinetics Nuvalent Grifols TG Therapeutics Viking Therapeutics Axsome Therapeutics Krystal Biotech Organon & Co. Dyne Therapeutics (NASDAQ:DYN) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, community ranking, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Do insiders and institutionals hold more shares of DYN or LEGN? 96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media prefer DYN or LEGN? In the previous week, Dyne Therapeutics had 4 more articles in the media than Legend Biotech. MarketBeat recorded 11 mentions for Dyne Therapeutics and 7 mentions for Legend Biotech. Legend Biotech's average media sentiment score of 0.43 beat Dyne Therapeutics' score of 0.24 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 0 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in DYN or LEGN? Legend Biotech received 48 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Dyne Therapeutics an outperform vote while only 71.79% of users gave Legend Biotech an outperform vote. CompanyUnderperformOutperformDyne TherapeuticsOutperform Votes3675.00% Underperform Votes1225.00% Legend BiotechOutperform Votes8471.79% Underperform Votes3328.21% Is DYN or LEGN more profitable? Dyne Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Legend Biotech's return on equity of -29.69% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -57.46% -51.62% Legend Biotech -66.92%-29.69%-19.45% Which has higher earnings and valuation, DYN or LEGN? Dyne Therapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$235.94M-$3.56-3.97Legend Biotech$285.14M20.92-$518.25M-$0.95-34.38 Do analysts rate DYN or LEGN? Dyne Therapeutics currently has a consensus price target of $49.91, suggesting a potential upside of 253.21%. Legend Biotech has a consensus price target of $80.62, suggesting a potential upside of 146.83%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Legend Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08Legend Biotech 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, DYN or LEGN? Dyne Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. SummaryDyne Therapeutics beats Legend Biotech on 11 of the 18 factors compared between the two stocks. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.44B$6.58B$5.36B$9.14BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-3.979.8389.4717.33Price / SalesN/A305.871,263.70136.49Price / CashN/A61.4443.7535.97Price / Book9.486.055.324.80Net Income-$235.94M$154.62M$122.60M$224.91M7 Day Performance-10.96%-1.68%0.69%1.77%1 Month Performance-45.99%-2.35%1.55%2.22%1 Year Performance-15.14%1.02%27.25%20.67% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics3.5695 of 5 stars$14.13-4.3%$49.91+253.2%-11.7%$1.44BN/A-3.97100Analyst ForecastLEGNLegend Biotech2.5041 of 5 stars$31.93-5.0%$80.62+152.5%-47.9%$5.83B$520.18M-33.611,800Short Interest ↓ELANElanco Animal Health4.4077 of 5 stars$11.56+1.1%$16.43+42.1%-20.6%$5.71B$4.45B28.909,800CYTKCytokinetics4.3108 of 5 stars$46.51-0.2%$83.64+79.8%-42.1%$5.49B$7.53M-8.64250Analyst ForecastNUVLNuvalent1.827 of 5 stars$73.03-4.7%$112.36+53.9%+2.4%$5.19BN/A-21.0540Analyst ForecastInsider TradeNews CoverageGRFSGrifols2.0473 of 5 stars$7.25-0.5%N/A-1.2%$4.98B$7.01B5.9426,300Positive NewsGap DownTGTXTG Therapeutics4.4921 of 5 stars$27.94-3.3%$40.67+45.5%+92.2%$4.35B$264.79M-279.37290Analyst ForecastAnalyst RevisionNews CoverageVKTXViking Therapeutics3.9223 of 5 stars$39.00-0.8%$106.75+173.7%+53.2%$4.35BN/A-41.9420Analyst ForecastAXSMAxsome Therapeutics4.6349 of 5 stars$88.67+10.8%$129.43+46.0%+10.3%$4.30B$338.46M-13.58380Analyst RevisionKRYSKrystal Biotech4.8277 of 5 stars$148.85-2.7%$206.67+38.8%+14.1%$4.28B$241.52M84.10229Short Interest ↓Positive NewsOGNOrganon & Co.4.8084 of 5 stars$15.61-1.5%$21.33+36.7%-2.5%$4.02B$6.41B3.1010,000Positive News Related Companies and Tools Related Companies Legend Biotech Competitors Elanco Animal Health Competitors Cytokinetics Competitors Nuvalent Competitors Grifols Competitors TG Therapeutics Competitors Viking Therapeutics Competitors Axsome Therapeutics Competitors Krystal Biotech Competitors Organon & Co. Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DYN) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
